References of "Paquot, Nicolas"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLa vignette thérapeutique de l'étudiant. Le choix entre un inhibiteur de la DPP-4 et un inhibiteur des SGLT2 pour traiter le diabète de type 2 (2016)
SCHEEN, André ULg; PAQUOT, Nicolas ULg

in Revue Médicale de Liège (2016), 71(12), 579-585

Summary : Two new classes of oral antidiabetic agents play an increasing role in the management of type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and sodiumglucose cotransporters ... [more ▼]

Summary : Two new classes of oral antidiabetic agents play an increasing role in the management of type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and sodiumglucose cotransporters type 2 (SGLT2) inhibitors (gliflozins). After failure of a monotherapy with metformin (first pharmacological choice in type 2 diabetes), both may offer an alternative to the add-on of a sulphonylurea, especially in patients at risk of hypoglycaemia. However, the choice between a DPP-4 inhibitor and a SGLT2 inhibitor is not easy and should be oriented based upon the individual patient characteristics. The arguments in favour of one or another pharmacological class are discussed, considering a clinical case of a patient with coronary heart disease and type 2 diabetes not well controlled with metformin. [less ▲]

Detailed reference viewed: 11 (0 ULg)
See detailInvolvement of membrane remodelling induced by fatty acids in the regulation of the NLRP3 inflammasome activity in human macrophages
Gianfrancesco, Marco ULg; Dehairs, Jonas; Bloch, Katerzina et al

Poster (2016, September 12)

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailProtection cardiovasculaire et rénale du patient diabétique de type 2 : le point après EMPA-REG OUTCOME et LEADER
SCHEEN, André ULg; PIERARD, Luc ULg; KRZESINSKI, Jean-Marie ULg et al

in Revue Médicale de Liège (2016), 71(09), 376-381

Summary : Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a ... [more ▼]

Summary : Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with T2D and high cardiovascular risk : empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER. Both medications showed a significant reduction in major cardiovascular events (-14 and -13 %, respectively), cardiovascular mortality (-38 and -22%), all-cause mortality (-32 and -15 %) and renal events (-39 et -22 %). The underlying protective mechanisms remain controverted. Ongoing studies should allow to decide whether the benefits are specific to each molecule or may be attributed to a class effect. [less ▲]

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailLa vignette diagnostique de l’étudiant Mise au point d’une suspicion de malaise hypoglycémique chez une personne adulte non diabétique
SCHEEN, André ULg; PAQUOT, Nicolas ULg; LEFEBVRE, Pierre ULg

in Revue Médicale de Liège (2016), 71(09), 407-413

Résumé : La survenue de malaises est souvent attribuée à une hypoglycémie chez des personnes non diabétiques et, a priori, sans autre problème de santé. Ce diagnostic est, cependant, souvent galvaudé, car ... [more ▼]

Résumé : La survenue de malaises est souvent attribuée à une hypoglycémie chez des personnes non diabétiques et, a priori, sans autre problème de santé. Ce diagnostic est, cependant, souvent galvaudé, car habituellement non clairement démontré. Le diagnostic d’hypoglycémie doit se faire de façon structurée en se basant sur la triade de Whipple. Tout d’abord, l’anamnèse doit rechercher les symptômes évocateurs d’hypoglycémie, adrénergiques et neuroglucopéniques. Ensuite, l’hypoglycémie doit être authentifiée par une mesure d’une valeur basse au moment d’un malaise. Enfin, s’il s’agit bien d’une hypoglycémie, le malaise doit disparaître rapidement après resucrage. Une fois le diagnostic posé sur la base de cette triade, l’anamnèse doit faire préciser, outre la sévérité des malaises, leur chronologie, après les repas ou à jeun, ce qui oriente vers une hypoglycémie réactive, fonctionnelle, ou vers une hypoglycémie d’origine organique (insulinome). Des examens complémentaires, faisant d’abord appel à la biologie clinique, ensuite éventuellement à l’imagerie médicale, permettront de, non seulement confirmer le diagnostic d’hypoglycémie, mais aussi d’en préciser l’origine, ce qui orientera la stratégie thérapeutique. [less ▲]

Detailed reference viewed: 21 (7 ULg)
Full Text
See detailLes bienfaits du sport sur la santé de la personne diabétique
PAQUOT, Nicolas ULg

in Revue de l'ABD (2016)

Detailed reference viewed: 37 (1 ULg)
See detailLe diabète et la sélection médicale
PAQUOT, Nicolas ULg

Conference (2016, April 27)

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailEnergy and nutrient content of food served and consumed by nursing home residents
Buckinx, Fanny ULg; ALLEPAERTS, Sophie ULg; PAQUOT, Nicolas ULg et al

in the journal of nutrition, health & aging (2016), in press

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food ... [more ▼]

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food intake and dietary allowances. Design: This is a cross sectional study. Setting: This study was performed in nursing homes. Participants: Residents of these 2 nursing homes were eligible for the study if they agreed to participate and if they meet the selection criteria (to be older than 65 years and have a regular texture diet). Measurement: Nutrient content of the served food and real food consumption was calculated for all meals during a 5-day period by precise weighting method. Difference between consumed and served dietary content was evaluated by the Chi² test. Results: Seventy-four Belgian nursing home residents (75% of women, 85.8 ± 7.04 years on average) were included in this study. These subjects had a mean body mass index of 24.9 ± 4.83 kg/m². The mean energy content of the served food was 1783.3 ± 125.7 kcal per day. However, residents did not eat the whole of the meals and the actual energy content of the consumed food was significantly less (1552.4 ± 342.1 kcal per day; p<.001). The average protein content of the food served was equal to 0.96 ± 0.20 g/kg/day and the average consumption of protein by the residents was 0.88 ± 0.25 g/kg/day. The difference between protein served and consumed was also significant (p=.04). Moreover, people considered as well nourished, eating significantly more energy than the others (p=.04). Conclusion: Meals served in nursing homes are not entirely consumed by their residents. As expected, the energy consumed are lower in subjects considered as malnourished or at risk of malnutrition. [less ▲]

Detailed reference viewed: 23 (8 ULg)
Full Text
Peer Reviewed
See detailL’ÉTUDE CLINIQUE DU MOIS TECOS : confirmation de la sécurité cardiovasculaire de la sitagliptine
SCHEEN, André ULg; PAQUOT, Nicolas ULg

in Revue Médicale de Liège (2015), 70

Summary : The cardiovascular safety of sitagliptin has been evaluated in TECOS («Trial Evaluating Cardiovascular Outcomes with Sitagliptin»). TECOS recruited patients with type 2 diabetes and a history of ... [more ▼]

Summary : The cardiovascular safety of sitagliptin has been evaluated in TECOS («Trial Evaluating Cardiovascular Outcomes with Sitagliptin»). TECOS recruited patients with type 2 diabetes and a history of cardiovascular disease who received, as add-on to their usual therapy, either sitagliptin (n = 7.257) or placebo (n = 7.266), with a median follow-up of 3 years. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95 % confidence interval, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95 % CI, 0.83 to 1.20; P=0.98). The cardiovascular safety of sitagliptin, which was already shown in meta-analyses of phase II-III randomised controlled trials and in observational cohort studies in real life, is now confirmed in the landmark prospective cardiovascular outcome study TECOS. [less ▲]

Detailed reference viewed: 47 (2 ULg)
Full Text
Peer Reviewed
See detailEnergy and nutrient contents of food served and consumed by nursing home residents
Buckinx, Fanny ULg; Paquot, Nicolas ULg; Allepaerts, Sophie ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 46 (10 ULg)
See detailDeciphering the molecular mechanisms underlying NLRP3 inflammasome activation by saturated fatty acids
Gianfrancesco, Marco ULg; Bloch, Katarzyna; Dehairs, Jonas et al

Poster (2015, September)

Detailed reference viewed: 39 (16 ULg)
Full Text
Peer Reviewed
See detailCOMPARISON OF DIABETES CONTROL ONE YEAR AFTER GASTRIC BYPASS AND MAGENSTRASSE AND MILL PROCEDURES
SCHLECK, Michael ULg; KOHNEN, Laurent ULg; DE FLINES, Jenny ULg et al

Poster (2015, May)

Bariatric surgery has become a main therapy of type 2 diabetes in the obese population. The best surgical procedure to achieve diabetes control remains debated. Gastric bypass would be the preferred ... [more ▼]

Bariatric surgery has become a main therapy of type 2 diabetes in the obese population. The best surgical procedure to achieve diabetes control remains debated. Gastric bypass would be the preferred option according to its incretin stimulating potential. We compared in this study gastric bypass surgery to a pure restrictive procedure in terms of diabetes control at 1 year. [less ▲]

Detailed reference viewed: 76 (4 ULg)
Full Text
See detailCholestérol haut, cholestérol bas: quels sont les risques en gériatrie ?
ANCION, Arnaud ULg; PAQUOT, Nicolas ULg; BOLAND, BENOIT et al

Scientific conference (2015, March 19)

Detailed reference viewed: 44 (3 ULg)
Full Text
Peer Reviewed
See detailEnergy and nutrient contents of food served and consumed by nursing home residents
Buckinx, Fanny ULg; PAQUOT, Nicolas ULg; ALLEPAERTS, Sophie ULg et al

in The Journal of Nursing Home Research Sciences (2015), 1

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailInflammatory markers and cardiometabolic diseases.
ESSER, Nathalie ULg; Paquot, Nicolas ULg; Scheen, André ULg

in Acta clinica Belgica (2015), 70(3), 193-9

OBJECTIVES: A growing body of evidence emerges that obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease are intimately related to chronic inflammation. METHODS: A narrative review ... [more ▼]

OBJECTIVES: A growing body of evidence emerges that obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease are intimately related to chronic inflammation. METHODS: A narrative review summarizing the most recent data of the literature describing the pathological implications of inflammation in obese patients with cardiometabolic disorders. RESULTS: Besides high-sensitive C-reactive protein, various circulating or in situ inflammatory markers have been identified, presumably reflecting the presence of inflammation in various key-organs (visceral adipose tissue, skeletal muscle, pancreatic islets, liver, intestine, arterial wall). Available data support the concept that targeting inflammation, not only reduces systemic inflammatory markers, but also improves insulin sensitivity and ameliorates glucose control in insulin-resistant patients, thus potentially reducing the risk of cardiovascular complications. CONCLUSION: These observations confirm the role of inflammation in cardiometabolic diseases and support the development of pharmacological strategies that aim at reducing inflammation, especially in patients with type 2 diabetes. [less ▲]

Detailed reference viewed: 40 (12 ULg)
Full Text
Peer Reviewed
See detailAntidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
Scheen, André ULg; ESSER, Nathalie ULg; Paquot, Nicolas ULg

in Diabetes & metabolism (2015)

A growing body of evidence is emerging to show that abdominal obesity, the metabolic syndrome, type 2 diabetes, cardiovascular disease and microvascular diabetic complications are intimately related to ... [more ▼]

A growing body of evidence is emerging to show that abdominal obesity, the metabolic syndrome, type 2 diabetes, cardiovascular disease and microvascular diabetic complications are intimately related to chronic inflammation. These observations pave the way to the development of new pharmacological strategies that aim to reduce silent inflammation. However, besides specific anti-inflammatory agents, glucose-lowering medications may also exert anti-inflammatory effects that could contribute to improved outcomes in diabetic patients. Most studies have used metformin, an AMP-activated protein kinase (AMPK) activator, and thiazolidinediones (TZDs), which act as peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists. Both pharmacological classes (considered insulin-sparing agents or insulin sensitizers) appear to have greater anti-inflammatory activity than insulin-secreting agents such as sulphonylureas or glinides. In particular, TZDs have shown the widest range of evidence of lowered tissue (visceral fat and liver) and serum inflammation. In contrast, despite reducing postprandial hyperglycaemia, the effect of alpha-glucosidase inhibitors on inflammatory markers appears rather modest, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and glucagon-like peptide-1 (GLP-1) receptor agonists appear more promising in this respect. These incretin-based therapies exert pleiotropic effects, including reports of anti-inflammatory activity. No human data are available so far regarding sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Although they may have indirect effects due to reduced glucotoxicity, their specific mode of action in the kidneys does not suggest systemic anti-inflammatory activity. Also, in spite of the complex relationship between insulin and atherosclerosis, exogenous insulin may also exert anti-inflammatory effects. Nevertheless, for all these glucose-lowering agents, it is essential to distinguish between anti-inflammatory effects resulting from better glucose control and potential anti-inflammatory effects related to intrinsic actions of the pharmacological class. Finally, it would also be of major clinical interest to define what role the anti-inflammatory effects of these glucose-lowering agents may play in the prevention of macrovascular and microvascular diabetic complications. [less ▲]

Detailed reference viewed: 42 (10 ULg)
Full Text
Peer Reviewed
See detailActualisation 2015 du traitement de l'hyperglycemie dans le diabete de type 2.
Scheen, Andre ULg; Paquot, Nicolas ULg

in Revue medicale suisse (2015), 11(483), 15181520-5

The strategy for the management ot type 2 diabetes, summarized by a group of European and American experts, has been updated early 2015. A patient-centered approach is recommended and the first drug ... [more ▼]

The strategy for the management ot type 2 diabetes, summarized by a group of European and American experts, has been updated early 2015. A patient-centered approach is recommended and the first drug choice is metformin combined with lifestyle improvement. After failure of metformin monotherapy, the selection of a second drug should be based on the efficacy, safety and cost of each pharmacological class. When compared to the position statement of 2012, the most important changes are the possible addition of a gliptin to a dual oral therapy or even to insulin, the commercialization of sodium-glucose cotransporters type 2 (SGLT2) inhibitors (gliflozins, to be used in dual or triple therapy, even in combination with insulin) and the possible combination of a glucagon-like peptide-I receptor agonist together with a basal insulin. [less ▲]

Detailed reference viewed: 127 (3 ULg)